Clinical effectiveness of platelets in additive solution treated with two commercial pathogen‐reduction technologiesPaolo Rebulla, Giuliano Grazzini, Giorgio Gandini et al.|Transfusion|2017Cited by 75
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana LinfomiArmando Santoro, Francesco Merli, Rita Mazza et al.|Annals of Hematology|2021Cited by 2
Dataset related to article "Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi"Armando Santoro, Francesco Merli, Rita Mazza et al.|Zenodo (CERN European Organization for Nuclear Research)|2022Cited by 0
Dataset related to article "Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi"Armando Santoro, Francesco Merli, Rita Mazza et al.|Zenodo (CERN European Organization for Nuclear Research)|2022Cited by 0